<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">MicroTransponder</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:8422042a-1148-440a-9456-aa0e59b11f20;id=22137</id> <rights type="text">Copyright 2017, MicroTransponder</rights> <updated>2017-05-30T18:05:42Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/4W1V1VRVGPUiRbNhbFmw8w==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/4W1V1VRVGPUiRbNhbFmw8w==" /> <entry> <id>https://www.globenewswire.com/news-release/2017/05/30/1311022/0/en/MicroTransponder-Presents-Long-Term-Stroke-Trial-Data-at-INS-and-Announces-a-120-Patient-Pivotal-Stroke-Trial.html</id> <title type="text">MicroTransponder Presents Long Term Stroke Trial Data at INS and Announces a 120 Patient Pivotal Stroke Trial</title> <published>2017-05-30T18:05:42Z</published> <updated>2024-11-25T01:19:04Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/30/1311022/0/en/MicroTransponder-Presents-Long-Term-Stroke-Trial-Data-at-INS-and-Announces-a-120-Patient-Pivotal-Stroke-Trial.html" /> <content type="html"><![CDATA[<p><em><p>Late Breaking Long Term Clinical Study Results at the International Neuromodulation Society Conference Show Continued Improvement for Stroke Patients and a New 120 Patient Stroke Trial Will Begin Enrollment this Summer</p></em></p><p><span class="mw_region">DALLAS, TX</span><span>--(Marketwired - May 30, 2017) - </span>MicroTransponder, Inc., (<a href="http://www.microtransponder.com" rel="nofollow" title="www.microtransponder.com">www.microtransponder.com</a>) today unveiled new positive long-term positive clinical trial results from the Vivistimâ„¢ Stroke Rehabilitation trial. The objective of this multicenter, double-blind, randomized, active-controlled trial was to improve upper limb mobility in stroke survivors suffering chronic disability. The data was presented by Jesse Dawson M.D., University of Glasgow Hospital, and Teresa Kimberley, PhD, University of Minnesota Hospital. They presented the data to the clinicians gathered at the International Neuromodulation Society (INS) conference in Edinburgh, UK. The data showed 75% of patients had a clinically meaningful response on the Fugl-Meyer Upper Extremity Scale (FMUE) at the end of a six weeks of physical therapy compared to 33% for the control group. 90 days after the six weeks of physical therapy ended 88% of VNS patients had responded compared to 33% in the control arm. And during the long-term portion of the study average FMUE scores continued to increase, with the 6 month and 9 month data showing further gains. All responders indicated they believed their overall health had improved and were satisfied with the therapy.</p>]]></content> <dc:identifier>1311022</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>MicroTransponder</dc:contributor> <dc:modified>Thu, 22 Feb 2018 04:48 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2015/12/10/1311016/0/en/MicroTransponder-Clinical-Trial-Results-Published-in-Stroke-After-Company-Completes-a-5-5M-Round-of-Funding.html</id> <title type="text">MicroTransponder Clinical Trial Results Published in Stroke After Company Completes a $5.5M Round of Funding</title> <published>2015-12-10T16:58:36Z</published> <updated>2024-11-25T01:19:04Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2015/12/10/1311016/0/en/MicroTransponder-Clinical-Trial-Results-Published-in-Stroke-After-Company-Completes-a-5-5M-Round-of-Funding.html" /> <content type="html"><![CDATA[<p><em><p>The Prestigious American Heart Association Journal Stroke Has Published the Results of the Paired VNS Therapy for Stroke Patients With Reduced Upper Limb Mobility</p></em></p><p><span class="mw_region">DALLAS, TX</span><span>--(Marketwired - December 10, 2015) - </span>MicroTransponder, Inc., (<a href="http://www.microtransponder.com" rel="nofollow" title="www.microtransponder.com">www.microtransponder.com</a>) a privately-held medical device company, is pleased to announce that its successful stroke rehabilitation clinical trial has been published in the prestigious academic journal <em>Stroke</em>. The manuscript, titled "Safety, Feasibility and Efficacy of Vagus Nerve Stimulation (VNS) Paired with Arm Rehabilitation Following Ischemic Stroke" reports clinical results from a paired VNS therapy for stroke patients with significantly reduced upper limb mobility. This condition can incapacitate the patient and impede the ability to perform daily tasks required for independent living. <em>Stroke</em> is a peer-reviewed academic journal that is published monthly by the American Heart Association.</p>]]></content> <dc:identifier>1311016</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>MicroTransponder</dc:contributor> <dc:modified>Thu, 22 Feb 2018 04:48 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://www.marketwire.com/library/MwGo/2015/12/9/11G075155/Images/02_-_Vivistim-69f1e9006ad68001abe5c9ee9ca85cc1.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2015/12/10/1311016/0/en/MicroTransponder-Clinical-Trial-Results-Published-in-Stroke-After-Company-Completes-a-5-5M-Round-of-Funding.html"> <img src="http://www.marketwire.com/library/MwGo/2015/12/9/11G075155/Images/02_-_Vivistim-69f1e9006ad68001abe5c9ee9ca85cc1.jpg" width="600" align="left" border="0" alt="Photo" title="Vivistim device" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <media:content medium="image" type="image/jpeg" width="600" url="http://www.marketwire.com/library/MwGo/2015/12/9/11G075155/Images/Patient-with-therapist-STROKE,-no-Page-Header-f3db40e03d8f9ad2af2248f6422ffc13.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2015/12/10/1311016/0/en/MicroTransponder-Clinical-Trial-Results-Published-in-Stroke-After-Company-Completes-a-5-5M-Round-of-Funding.html"> <img src="http://www.marketwire.com/library/MwGo/2015/12/9/11G075155/Images/Patient-with-therapist-STROKE,-no-Page-Header-f3db40e03d8f9ad2af2248f6422ffc13.jpg" width="600" align="left" border="0" alt="Photo" title="Vivistim Stroke Therapy" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <media:content medium="image" type="image/jpeg" width="600" url="http://www.marketwire.com/library/MwGo/2015/12/9/11G075155/Images/Scientific_Diagram_of_Stroke_Therapy-e431ea867d02bfdaae62bdd53f9c7107.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2015/12/10/1311016/0/en/MicroTransponder-Clinical-Trial-Results-Published-in-Stroke-After-Company-Completes-a-5-5M-Round-of-Funding.html"> <img src="http://www.marketwire.com/library/MwGo/2015/12/9/11G075155/Images/Scientific_Diagram_of_Stroke_Therapy-e431ea867d02bfdaae62bdd53f9c7107.jpg" width="600" align="left" border="0" alt="Photo" title="Stroke Therapy Diagram" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:keyword>stroke</dc:keyword> <dc:keyword>VNS</dc:keyword> <dc:keyword>vagus nerve stimulation</dc:keyword> <dc:keyword>stroke rehabilitation</dc:keyword> <dc:keyword>stroke trial</dc:keyword> <dc:keyword>stroke study</dc:keyword> </entry> </feed>